PEA for Chemotherapy-Induced Peripheral Neuropathy (CIPN): What Cancer Patients Should Know
PEA for chemotherapy-induced neuropathy: a promising 2011 pilot, a 2024 phase II trial with a different result, and what cancer patients should know.
PEA for chemotherapy-induced neuropathy: a promising 2011 pilot, a 2024 phase II trial with a different result, and what cancer patients should know.
What the sciatica evidence for PEA rests on: a post hoc reanalysis, newer delivery research, and how it differs from PEA’s other pain evidence.
When to take palmitoylethanolamide timing: practical guidance on food co-ingestion, daily dosing windows, and absorption, what current evidence supports.
Compare palmitoylethanolamide (PEA) and pregabalin (Lyrica) for neuropathic pain: mechanisms, evidence, side effects, and practical considerations.
How does PEA compare to ibuprofen and naproxen for inflammatory pain? We examine the mechanisms, clinical evidence, and safety profiles of both.
Comparing palmitoylethanolamide (PEA) and magnesium for fibromyalgia: how each works, what the research shows, and what to know before trying either.
PEA and LDN take different paths to address pain and neuroinflammation. Here’s an honest look at how their mechanisms, evidence, and tradeoffs compare.
PEA and CBD both target inflammation and discomfort through distinct pathways. Learn the key differences, shared ground, and which may suit your situation.
Explore how palmitoylethanolamide (PEA) may combine with luteolin, omega-3s, and other supplements: mechanisms, practical considerations, and honest caveats.
Explore how PEA (palmitoylethanolamide) may support sleep quality by reducing pain and neuroinflammation. Evidence-based, honest review.
A review of clinical trial and systematic review data on palmitoylethanolamide (PEA) side effects, tolerability, and who should exercise caution.
PEA safety in pregnancy and breastfeeding: what preclinical data, breast milk research, and critical evidence gaps actually show.